The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA ...
CAMBRIDGE, MA - The U.S. Food and Drug Administration (FDA) has notified biotechnology company Moderna , Inc. (NASDAQ:MRNA) that it will not meet the May 12, 2024, deadline to complete the review ...
Some results have been hidden because they may be inaccessible to you